Positive attributes of anti-TERT CD4 T-helper type 1 immune responses in melanoma
Nardin et al's (2021) study on melanoma reports anti-TERT CD4 T helper type (Th) 1 responses in more than half of patients. Besides indicating a trend for improved survival, increased anti-TERT CD4 Th1 responses predicted better outcomes for patients treated with immune checkpoint inhibitors. T...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Dokumenttyp: | Article (Journal) Editorial |
| Sprache: | Englisch |
| Veröffentlicht: |
2022
|
| In: |
The journal of investigative dermatology
Year: 2022, Jahrgang: 142, Heft: 2, Pages: 279-281 |
| ISSN: | 1523-1747 |
| DOI: | 10.1016/j.jid.2021.09.005 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.jid.2021.09.005 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S0022202X21022697 
|
| Verfasserangaben: | Eduardo Nagore, Amaya Virós and Rajiv Kumar |
| Zusammenfassung: | Nardin et al's (2021) study on melanoma reports anti-TERT CD4 T helper type (Th) 1 responses in more than half of patients. Besides indicating a trend for improved survival, increased anti-TERT CD4 Th1 responses predicted better outcomes for patients treated with immune checkpoint inhibitors. Thus, harnessing systemic anti-TERT CD4 Th1 responses together with tumor-specific elevation of telomerase can potentially open new avenues for biomarkers and treatment in melanoma. |
|---|---|
| Beschreibung: | Version of record 20 January 2022 Gesehen am 27.04.2022 |
| Beschreibung: | Online Resource |
| ISSN: | 1523-1747 |
| DOI: | 10.1016/j.jid.2021.09.005 |